Retail / pharmacy · Deep dive

Walgreens Boots Alliance

The 124-year-old pharmacy chain that fell from a $100B+ market cap in 2015 to an $11.45-a-share take-under — bought by Sycamore Partners in August 2025 with 83% debt financing, chopped into five companies on day one, and now being run by the Staples playbook while PBM reimbursement grinds the core business toward zero.

at risk

Sycamore layered $18B of debt at 83% leverage onto a dispensing business whose US retail pharmacy segment ran a negative 5% operating margin, in a market where PBMs set the prices, Rite Aid is already dead, and the sponsor's own track record (Nine West, Limited, Belk) says extraction, not reinvention.

My take ★★ Very interesting ★ Interesting − Maybe ✗ Not interesting

Snapshot

Walgreens is the second-largest prescription dispenser in the United States — roughly 7,960 drugstores and $90.8B of 2025 prescription revenue per Drug Channels — and, since August 28, 2025, the biggest leveraged buyout of a healthcare retailer ever attempted. Sycamore Partners paid $11.45 a share, about $10B of equity in a deal worth up to $23.7B with debt and contingent payments, for a company worth more than $100B in 2015. At close, Sycamore split the conglomerate into five standalone companies, installed Staples veteran Mike Motz as Walgreens CEO, and began selling the pieces. The page-one question is whether private-equity surgery can fix a business whose core product is priced by its adversaries: the pharmacy benefit managers that reimburse most of every script Walgreens fills.

Founding story

Charles R. Walgreen Sr., the son of Swedish immigrants raised in Dixon, Illinois, bought a cramped drugstore on Chicago’s South Side in 1901 and proceeded to invent the American drugstore: bright lighting, wide aisles, a soda fountain and lunch counter (a Walgreens employee is credited with the malted milkshake in 1922), and relentless corner-lot expansion. By the late 1920s there were more than 500 stores; the company went public in 1927 and paid a dividend without interruption from 1933 until January 2025 — 92 years.

The modern entity is really Stefano Pessina’s creation. The Italian billionaire rolled up European drug distribution into Alliance Unichem, merged it with Boots in 2006, and took Alliance Boots private with KKR in 2007 in what was then Europe’s largest LBO. Walgreens bought 45% of Alliance Boots for $6.7B in 2012 and the rest in December 2014, forming Walgreens Boots Alliance with Pessina as CEO from 2015. The ownership history since is financial engineering substituting for operational renewal: a blocked Rite Aid merger converted into a $4.375B purchase of 1,932 Rite Aid stores (2017), a $70B KKR take-private flirtation (2019), Rosalind Brewer’s healthcare pivot (2021-2023), Tim Wentworth’s triage (2023-2025), and finally Sycamore — founded in 2011 by Stefan Kaluzny and Peter Morrow to buy declining retail cheap, best known for Staples, Talbots, Nine West, The Limited, and Belk.

How it works

The physical mechanics: a customer’s prescription arrives electronically, a pharmacist verifies and dispenses it, and the store bills not the patient but a pharmacy benefit manager — CVS Caremark, Express Scripts, or OptumRx, which together control roughly 80% of US prescription claims. The PBM decides the reimbursement rate, and this is where the model breaks. Reimbursement on generics (the vast majority of scripts) has been compressed to the point where a pharmacy can be paid less than its cost to acquire and dispense the drug; DIR fees — retroactive clawbacks assessed weeks or months after dispensing — grew an estimated 45,000% between 2010 and 2020 before partial reform. Contracts are take-it-or-leave-it: refuse the rate and lose access to every patient in that network. The result, per CNBC’s 2024 analysis, is that Walgreens’ US retail pharmacy operating margin fell from 4.4% in 2015 to 3.9% in 2019 to roughly negative 5% in 2024. CVS suffers the same pressure but owns Caremark, so a slice of the squeeze stays in-house. Walgreens owns no PBM and no insurer; it is a pure price-taker on roughly three-quarters of its revenue.

The historical offset was the front of store: the convenience basket a customer grabbed while waiting. That subsidy collapsed — Amazon took the planned purchases, dollar stores took the low-income trip, and shrink and locked cabinets degraded the rest. Services (vaccinations, testing) spiked during COVID, then normalized. Underneath sits a heavy fixed-cost base: 15,000-square-foot boxes, long operating hours, and a pharmacist labor force in open revolt over workload.

Product and business overview

US retail pharmacy. The core: ~7,960 stores (early 2026) dispensing on the order of a billion 30-day-equivalent prescriptions a year, plus immunizations and clinical services. This is what Sycamore’s Walgreens entity now is, full stop.

Front-of-store retail. Convenience, health and beauty, consumables — roughly a quarter of US segment sales, in structural decline for a decade.

The Boots Group. The UK’s leading pharmacy-beauty chain plus the No7 brands; £7.5B of fiscal 2025 revenue with pre-tax profit up 25% to £337M — ironically the healthiest asset in the empire, now in ~$10B sale talks.

VillageMD / Summit Health / CityMD, Shields, CareCentrix. The remains of the healthcare pivot: primary-care clinics Walgreens poured $6B+ into (a $5.2B controlling stake in 2021, $3.5B toward VillageMD’s $8.9B Summit Health deal in 2022), then wrote down by $5.8B in March 2024 and a further $3.0B in early 2025. All now sit outside Walgreens as separate Sycamore-controlled companies, with former shareholders holding CVRs worth up to $3.00/share against their monetization.

Business model and pricing

Revenue is booked as gross prescription revenue at PBM-adjudicated rates plus front-end retail sales — which means Walgreens does not set the price on most of what it sells. Drug Channels puts its 2025 US prescription revenue at $90.8B, about 12% of the $751B national dispensing market. Cash-pay generics leak to GoodRx coupons and Cost Plus Drugs; branded scripts carry high revenue but thin, clawback-exposed margin. The equity story under Sycamore is therefore not a pricing story at all — it is a cost and asset story: close 1,200+ stores, cut corporate overhead (628 jobs in early 2026), automate central fill via robotic micro-fulfillment, shrink the box toward pharmacy-only formats, and sell the non-US assets to pay down an $18.3B debt stack financed at 83.4% leverage — double the 41% average for 2024 buyouts (PitchBook). Sycamore’s equity check was roughly $2.5B; a Boots sale near the reported $10B would return the sponsor’s basis several times over before the US turnaround is even attempted.

Traction over time

Note the trap in the top line: revenue grew through 2024 even as the business bled, because branded-drug inflation swells prescription revenue without adding margin. The honest series is the operating margin (4.4% to negative 5% in nine years), the dividend (cut 48%, then suspended), and the store count, now in managed retreat.

Market analysis

US prescription dispensing revenue hit $751B in 2025, up 10% year over year (Drug Channels); the retail pharmacy market is variously sized around $670-676B for 2025 with ~4% CAGR projections (Persistence, Market Data Forecast). Demand is not the problem — aging demographics and chronic disease guarantee script growth. The structure is. More than 7,000 US pharmacies closed from 2022 through 2024, 2,800 in 2024 alone; roughly one in seven Americans now lives in a pharmacy desert. The Big Three PBMs’ 80% claim share lets them price dispensing at or below cost, and dispensing is what Walgreens does. Volume is migrating to mail, to Amazon’s hub-embedded pharmacies, and to whoever survives consolidation — Rite Aid’s 2025 liquidation released billions of scripts to the survivors, a genuine tailwind. GLP-1 drugs swell revenue at famously thin margins. The picture: a growing market whose economics are captured almost entirely upstream of the counter.

Competitive intel

CVS Health ($372.8B revenue, 2024) is the integrated giant — drugstores plus Caremark plus Aetna — that partially pays itself the reimbursement it squeezes from everyone else; it out-dispenses Walgreens $119B to $90.8B (2025, Drug Channels). Amazon Pharmacy (~$1.8B projected 2025 revenue, ~0.3% of scripts in 2024) is embedding pharmacies in fulfillment hubs for 2-6 hour delivery, aimed at the maintenance-script customer who never visits a store. Walmart (~4,600 pharmacies) and Costco run pharmacy as traffic bait inside trips customers already make. Mark Cuban Cost Plus Drugs resets the cash-generic price umbrella with cost-plus-15% transparency. Dollar General and the dollar channel already took the front-end basket. Walgreens’ remaining edges — density, pharmacist trust, Rite Aid’s released volume — are real, and none of them fix reimbursement.

History and evolution

• 1901 — Charles R. Walgreen Sr. buys his Chicago drugstore; 1927 — IPO; ~1930 — 500+ stores.
• 2007 — Pessina and KKR take Alliance Boots private (Europe’s largest LBO to date).
• 2012 / Dec 2014 — Walgreens buys Alliance Boots in two steps; WBA formed; Pessina CEO 2015.
• 2015 — Market cap tops $100B. 2015-2017 — Rite Aid merger blocked; buys 1,932 Rite Aid stores for $4.375B instead.
• 2019 — KKR floats a ~$70B take-private; nothing closes.
• 2020-2021 — $1B then $5.2B into VillageMD; Alliance Healthcare sold to AmerisourceBergen for $6.5B; Rosalind Brewer (ex-Starbucks COO) becomes CEO (Jan 2021).
• 2022 — VillageMD buys Summit Health/CityMD for $8.9B; ~$5.7B multistate opioid settlement drives a $3.7B quarterly loss.
• Sept-Oct 2023 — Brewer exits abruptly; “Pharmageddon” pharmacist walkouts hit Walgreens, CVS, Rite Aid; Tim Wentworth (ex-Express Scripts) named CEO, launches $1B cost cuts.
• Jan-Mar 2024 — Dividend cut 48%; $5.8B VillageMD impairment.
• Oct 2024 — 1,200-store closure plan announced. Dec 2024 — Sycamore talks leak.
• Jan-Apr 2025 — Dividend suspended after 92 years; deal signed March 6 at $11.45/share; a further $3.0B VillageMD impairment; DOJ opioid settlement of up to $350M for illegally filled prescriptions.
• Aug 28, 2025 — Deal closes; Nasdaq delisting; five-way split; Mike Motz installed as Walgreens CEO.
• Late 2025-2026 — Boots enters ~$10B sale talks (Weston family, Sigma Healthcare among reported bidders), likely killing the London IPO path; 628 corporate/DC layoffs; ~350 closures slated for 2026; micro-fulfillment and smaller-format pivot.

What people say

The case for. Bulls argue Walgreens is a broken capital structure wrapped around a still-essential asset. It touches millions of Americans weekly, holds top-two dispensing share, and inherits Rite Aid’s released scripts. Private ownership removes the quarterly-earnings spiral and the dividend albatross; the five-way split forces the focus a conglomerate board never achieved. Motz is a genuine pharmacy operator (Shoppers Drug Mart), not just a Staples cost-cutter, and Sycamore’s early moves — keeping 2026 closures to ~350, fewer than feared, while investing in robotic central fill — read as surgery rather than strip-mining. Boots at ~$10B validates that the parts exceed the $10B equity price. Analysts sympathetic to the deal note Sycamore bought near the bottom of sentiment with a free CVR-shaped option on healthcare assets others wrote off.

The complaints. The Private Equity Stakeholder Project and Americans for Financial Reform warned before close that Sycamore’s playbook — Staples’ reported $1B dividend, 100+ store closures and 7,000+ layoffs; bankruptcies at Nine West and Belk; liquidation of The Limited; a ~$3M Talbots wage settlement — predicts job losses and pharmacy deserts; the 628 layoffs and DC closure within months of close alarmed exactly those watchdogs. Critics of the 83.4% debt financing note Sycamore can be made whole by asset sales alone, leaving the US pharmacy’s fate financially incidental. Employees are blunt: Walgreens sits at 3.0 on Glassdoor (2.9 for pharmacy staff, 33% would recommend), with recurring themes of chronic understaffing, vaccination quotas, no bathroom breaks, and safety-threatening workload — the grievances behind the 2023 Pharmageddon walkouts. Customers complain of shrinking hours, locked-up merchandise, and abrupt closures stranding prescriptions. And the opioid ledger — a ~$5.7B multistate settlement plus the 2025 DOJ deal — is a decade-long cash drain serviced alongside $18B of debt.

Outlook: well positioned or at risk?

Walgreens is at-risk. The bear case is not that Sycamore will fail to make money — it plausibly will, because Boots alone at the reported ~$10B could return the ~$2.5B equity check several times over, with Shields, CareCentrix, and the VillageMD parts as further coupons. The bear case is that the US pharmacy business has no visible path back to durable profitability under any owner. Its prices are set by three PBMs with 80% market power and every incentive to hold dispensing margins at zero; its front-end subsidy is gone; its labor force is demoralized to the point of national walkouts; and it now carries an $18.3B debt stack at 83% leverage against a segment that ran a negative 5% operating margin in 2024. The promising moves — micro-fulfillment automation, pharmacy-first small formats, harvesting Rite Aid’s orphaned scripts — shrink the cost base but do not change who controls reimbursement. Watch three tells through 2026-27: whether Boots proceeds go to debt paydown or sponsor distributions; whether closures stop near the 1,200 target or compound past it; and whether Walgreens gains or cedes script share as Rite Aid’s volume settles. A leaner, private, automated Walgreens can survive as a smaller cash machine for its sponsor. But well-positioned requires a moat, and a price-taker whose revenue is adjudicated by its competitors’ PBMs does not have one. This is a managed decline being executed competently — which is still a decline.

How a challenger would attack it

Attack the counter, not the store. Walgreens’ exploitable surface is threefold: a demoralized pharmacist workforce (Glassdoor 2.9 for pharmacy staff, 33% recommend, national walkouts), a customer experience degraded by shrinking hours and locked cabinets, and an owner whose $18.3B debt stack means every dollar goes to service leverage rather than reinvention. A challenger builds the pharmacy Amazon is already sketching — maintenance scripts filled from automated central pharmacies with 2-6 hour delivery — but adds what Amazon lacks: the clinical layer, recruiting Walgreens’ own pharmacists out of the box and into telehealth-plus-dispensing roles where they counsel instead of chase vaccination quotas. The 2023 Pharmageddon grievances are a hiring pipeline. On price, follow Cost Plus Drugs’ cost-plus-15% transparency for cash generics, which siphons exactly the scripts where chains made margin and makes Walgreens’ PBM-adjudicated pricing look like the scam consumers increasingly believe it is. Geographically, target the pharmacy deserts Walgreens itself is creating — 1,200+ closures, one in seven Americans already desert-resident — where Rite Aid’s released scripts plus Walgreens’ abandonments hand a delivery-first entrant customers with no alternative. Sycamore cannot respond: matching delivery economics or pharmacist pay requires capital the 83% leverage structure explicitly reserves for debt paydown and sponsor returns.

Same playbook, new buyer

The dispensing-plus-trust model still works — just not for PBM-adjudicated retail scripts. The most promising shift is the payer, not the product: employer-direct and cash-pay pharmacy, contracting with self-insured employers who are actively fleeing the Big Three PBMs, where the pharmacy is paid transparently per fill rather than clawed back via DIR fees. Walgreens cannot follow because its $90.8B of prescription revenue depends on staying inside the very PBM networks such a model exists to bypass — defecting means losing network access on three-quarters of its volume. A second shift is the format Sycamore is edging toward but cannot fund at scale: pharmacy-only micro-fulfillment serving pharmacy deserts by courier, without the 15,000-square-foot box, the front-end inventory, or the shrink. A third is demographic: the aging-in-place chronic-care patient, bundling adherence packaging, med sync, and pharmacist telehealth into a subscription — a service margin uncoupled from per-script reimbursement. Each of these takes the trusted-pharmacist asset Walgreens still owns and detaches it from the real-estate and PBM structures that are strangling it.

Sources and further reading

• Walgreens to go private in roughly $10 billion deal with Sycamore Partners — CNBC, March 6, 2025.
• Sycamore Partners closes Walgreens acquisition, splits retailer into 5 companies — Healthcare Dive, August 2025.
• Walgreens Boots Alliance LBO backed by $18B of debt — PitchBook, 2025.
• Sycamore Partners’ strategy has hurt workers, generated poor returns — Private Equity Stakeholder Project, 2025.
• Walgreens’ lost decade: how M&A mania and retail neglect shrunk a $100 billion giant — Fortune, June 17, 2025.
• Here’s why Walgreens and CVS retail pharmacies are struggling — CNBC, August 18, 2024.
• Walgreens takes $5.8 billion hit on VillageMD bet — Reuters via US News, March 28, 2024.
• Walgreens agrees to pay up to $350M for illegally filling unlawful opioid prescriptions — US Department of Justice, April 2025.
• The Top 15 US Pharmacies of 2025 — Drug Channels, March 2026.
• Boots enters sale talks as owners consider £10bn deal over IPO — Global Cosmetics News, 2026.
• Walgreens is laying off hundreds of workers; 2026 closure list smaller than feared — Yahoo Finance, February 2026.
• Pharmageddon 2023: Walgreens’ pharmacy employee walkout adds to struggles — Axios, October 31, 2023.